GET DAILY SIGNALSNuvectis Pharma (NVCT) Rises +15.7% Over 30 Days on Pipeline Momentum
Key Takeaways
- NVCT shares climbed roughly +15.7% over the trailing 30 days, rising from an $18.15 close on October 13, 2026, to a $21.00 close on November 11, 2026.
- The rebound was fueled by strong third-quarter financial results and fresh clinical momentum across the company's late-stage pipeline.
- Nuvectis reported approximately $140.7 million in cash and equivalents as of September 30, 2026, with an expected runway into the second half of 2029.
- Lead asset NXP100 (ciprocopan) is already approved in China for paroxysmal nocturnal hemoglobinuria (PNH) and is advancing along a U.S. regulatory path, with an FDA update anticipated before year-end.
- NXP200 secured breakthrough therapy designation in China and presented updated Phase 1b data at ESMO, including complete responses in recurrent gliomas.
- Despite the 30-day surge, the stock is up only about 7% over the trailing three months, reflecting a volatile path that included a steep pullback before the recent recovery.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
Nuvectis Pharma (NVCT) Company Overview and Market Position
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of complement-related conditions and oncology. Its pipeline is anchored by NXP100 (ciprocopan), a once-daily oral complement Factor B inhibitor, and NXP200, an oral, brain-penetrant "paradox-breaker" BRAF inhibitor for BRAF-mutated solid tumors. The company also continues development of NXP900, an SRC/YES1 kinase inhibitor.
In late June 2026, Nuvectis licensed ex-China rights to NXP100 and NXP200 from Haisco Pharmaceutical Group, a transaction that transformed the company into a late-stage developer. Investors follow NVCT closely because of its potential best-in-class assets, an expanding late-stage pipeline, and near-term regulatory catalysts in large markets such as PNH and IgA nephropathy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Nuvectis Pharma (NVCT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NVCT advanced approximately +15.7%, from an $18.15 close on October 13, 2026, to $21.00 on November 11, 2026. The move was not a straight line: the shares dipped below $18 intraday in late October and again in early November before rallying sharply following the company's third-quarter report.
The quarterly picture is more muted. Over the trailing three months, the stock is up roughly 7%, moving from around $19.54 in mid-August to $21.00. That modest net gain masks considerable volatility, as the shares climbed to an intraday high near $25.93 in late August, sold off to a mid-October low near $17.68, and then recovered through early November.
What Drove NVCT Stock Price in the Last 30 Days
The recent rally was driven primarily by two catalysts. First, Nuvectis reported third-quarter 2026 results on November 4, highlighting a cash position of about $140.7 million and a projected runway into the second half of 2029. Management framed the quarter as transformational, citing the late-June Haisco licensing deal and the July 2026 marketing approval of NXP100 in China for treatment-naive PNH patients, where the drug demonstrated superiority over Soliris in a Phase 3 study.
Second, in October NXP200 was featured in an oral presentation at ESMO. Updated Phase 1b data showed deep and durable single-agent activity, including complete responses in patients with recurrent or progressive gliomas, as well as responses in patients previously treated with a BRAF inhibitor. Combined with the September breakthrough therapy designation in China, the data reinforced the view that NXP200 could emerge as a differentiated, potentially best-in-class asset.
Investor sentiment also improved around NXP100's U.S. path. Management described constructive dialogue with the FDA and indicated an update on the regulatory path is expected before year-end.
What Drove NVCT Stock Performance Over the Last Quarter
The trailing three months were defined by a company-wide transformation. Nuvectis closed its ex-China licensing agreement for NXP100 and NXP200 in late June, then strengthened its balance sheet with a $115 million follow-on offering and additional ATM proceeds in July, ending the third quarter with roughly $140.7 million in cash.
These milestones drove the stock's late-August surge above $25, as investors repriced the company from an early-stage oncology developer into a late-stage pipeline with near-term catalysts. A subsequent pullback through September and mid-October reflected profit-taking and the inherent binary risk of biotech development, before the ESMO data and third-quarter report re-established positive momentum. The quarter also brought continued progress on NXP900, whose Phase 1b program includes osimertinib and lorlatinib combination studies.
NVCT Stock Forecast Drivers: What Investors Should Watch Next
Several near-term catalysts could shape NVCT's trajectory. Investors will be watching for the company's year-end update on the FDA regulatory path for NXP100 in PNH, as well as the expected first-quarter 2027 decision on the second China marketing application for previously treated PNH patients. Additional read-throughs from ongoing Phase 2 and Phase 3 studies in IgA nephropathy and related indications could also influence sentiment.
For NXP200, a U.S. IND filing is targeted for year-end 2026, with a Phase 1b trial expected to begin in early 2027. Competition remains a key risk: Novartis' (NVS) Fabhalta is already approved in multiple indications, and AstraZeneca's (AZN) injectable C5 inhibitors continue to dominate established markets. Execution on regulatory filings, clinical timelines, and manufacturing transfer remain important variables for investors to monitor.
Exploring AI Trading Strategies
One resource I turn to for additional perspective is Tickeron’s Trending AI Robots. The page highlights top-performing automated strategies across different timeframes and tickers, which can help complement fundamental research when evaluating names like NVCT. It offers a practical way to see how data-driven approaches align with market movements without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
NVCT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVCT turned positive on November 06, 2026. Looking at past instances where NVCT's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NVCT as a result. In 92 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
NVCT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCT advanced for three days, in 250 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
NVCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for NVCT entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NVCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NVCT's P/B Ratio (75.158) is slightly higher than the industry average of (3.498). P/E Ratio (-15.841) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement